Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01817530
Other study ID # M12-813
Secondary ID 2013-000082-37
Status Completed
Phase Phase 2
First received
Last updated
Start date April 8, 2013
Est. completion date December 2015

Study information

Verified date June 2020
Source AbbVie
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 2b randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of elagolix alone and in combination with add-back therapy versus placebo on heavy menstrual bleeding in premenopausal women 18 to 51 years of age with uterine fibroids.


Recruitment information / eligibility

Status Completed
Enrollment 571
Est. completion date December 2015
Est. primary completion date June 2015
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 51 Years
Eligibility Inclusion Criteria:

- Subject is pre-menopausal female 18 to 51 years of age at Screening.

- Subject has diagnosis of uterine fibroids documented by a Pelvic Ultrasound.

- Subject has heavy uterine bleeding associated with uterine fibroids.

Exclusion Criteria:

- Subject has had a myomectomy, uterine artery embolization or high intensity focused ultrasound for fibroid destruction within 6 months prior to Screening or endometrial ablation within 5 years prior to Screening.

- Subject has a history of osteoporosis or other metabolic bone disease.

- Subject shows evidence of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric (including depression, schizophrenia, bipolar disorder), or neurologic diseases or any uncontrolled medical illness such as uncontrolled type 2 diabetes. Subject has any history of attempted suicide.

- Subject has a history of clinically significant condition(s) including but not limited to: * Symptomatic Endometriosis * Epilepsy or seizures * Type 1 diabetes * Chronic kidney disease * Any cancer (except treated basal cell carcinoma of the skin), including breast or ovarian cancer or subject has taken any systemic cancer chemotherapy

Study Design


Intervention

Other:
Elagolix placebo
oral coated tablet
Drug:
Elagolix
oral coated tablet
0.5 mg estradiol / 0.1 mg norethindrone acetate
oral hard capsule
1 mg estradiol / 0.5 mg norethindrone acetate
oral hard capsule
E2/NETA placebo
oral hard capsule

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
AbbVie

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With a Menstrual Blood Loss (MBL) Volume of < 80 mL at the Final Month and a = 50% Reduction in MBL Volume From Baseline to the Final Month The percentage of participants meeting a composite endpoint consisting of these 2 bleeding assessments: a MBL Volume of < 80 mL at the Final Month and a =50% Reduction in MBL Volume from Baseline to the Final Month (last 28 days of treatment). Baseline is defined as the last qualified menstrual cycle during the screening period. Baseline, Final Month (last 28 days of treatment)
Secondary Percentage of Participants With a MBL Volume < 80 mL and a = 50% Reduction in MBL Volume From Baseline During the Last 56 to 29 Days of Treatment The percentage of participants meeting a composite endpoint consisting of these 2 bleeding assessments: a MBL volume < 80 mL and a = 50% reduction in MBL volume from baseline during the last 56 to 29 days of last treatment. Baseline is defined as the last qualified menstrual cycle during the screening period. Baseline, second last 28 days of treatment (last 56 to 29 days of treatment)
Secondary Percentage of Participants With a MBL Volume < 80 mL and a = 50% Reduction in MBL Volume From Baseline During the Last 84 to 57 Days of Treatment The percentage of participants meeting a composite endpoint consisting of these 2 bleeding assessments: a MBL volume < 80 mL and a = 50% reduction in MBL volume from baseline during the last 84 to 57 days of last treatment. Baseline is defined as the last qualified menstrual cycle during the screening period. Baseline, third last 28 days of treatment (last 84 to 57 days of treatment)
Secondary Percentage of Participants Who Achieved an MBL Volume of < 80 mL at the Final Month Percentage of participants who achieved an MBL volume of < 80 mL at the Final Month (last 28 days of treatment). Baseline is defined as the last qualified menstrual cycle during the screening period. Final Month (last 28 days of treatment)
Secondary Percentage of Participants With a = 50% Reduction in MBL Volume From Baseline to the Final Month Percentage of participants with a >= 50% reduction from baseline in MBL to the Final Month (last 28 days of treatment). Baseline is defined as the last qualified menstrual cycle during the screening period. Baseline, Final Month (last 28 days of treatment)
Secondary Percentage of Participants Who Achieved Amenorrhea During the Last 56 Days of Treatment Amenorrhea is defined as having 0 days of bleeding or spotting based on observed validated and nonvalidated alkaline hematin data and having 0 days of bleeding or spotting, based on imputed electronic diary data during the last 56 days of treatment. Participants needed to have at least 66 days on treatment. Last 56 days of treatment (after 10 days from first dose date)
Secondary Percentage of Participants Who Achieved Suppression of Bleeding During the Last 56 Days of Treatment Suppression of bleeding is defined as having 0 days of bleeding based on observed validated and nonvalidated alkaline hematin data and having 0 days of bleeding (spotting is allowed) based on imputed electronic diary data during the last 56 days of treatment. Last 56 days of treatment (after 10 days from first dose date)
Secondary Mean Change in the Number of Bleeding Days From Baseline to Month 6 The number of days with any bleeding including spotting was calculated using data collected on daily bleeding diary. Baseline is defined as the last 28 days prior to the first dose day of study drug. Baseline, Month 6
Secondary Mean Change in the Number of Heavy Bleeding Days From Baseline to Month 6 The number of days with heavy bleeding (either heavy or very heavy/gushing bleeding) was calculated using data collected on daily bleeding diary. Baseline is defined as the last 28 days prior to the first dose day of study drug. Baseline, Month 6
Secondary Change in Bleeding Severity Scores From Baseline at the Final Month The average bleeding score was calculated for each 28-day interval starting on Day 29 using data collected on daily bleeding diary using the Mansfield-Voda-Jorgenson (MVJ) Menstrual Bleeding Scale (1=spotting, 2 = very light bleeding, 3 = light bleeding, 4 = moderate bleeding, 5 = heavy bleeding, 6 = very heavy/gushing bleeding). Baseline is defined as the last 28 days prior to the first day of study drug. Baseline, Final Month (last 28 days of treatment)
Secondary Mean Change in Hemoglobin Concentration From Baseline to Final Visit Baseline is defined as the last measurement prior to the first dose of study drug. Baseline, Final Visit during treatment period (Month 6 or early termination)
Secondary Mean Percentage Change From Baseline in Total Fibroid Volume at Month 3, Month 6, and Final Visit Volume of the total fibroid volume (3 largest fibroids), as measured by transvaginal ultrasound, or transabdominal ultrasound. Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)
Secondary Mean Percentage Change From Baseline in Primary Fibroid Volume at Month 3, Month 6, and Final Visit Volume of the largest fibroid (primary fibroid), as measured by transvaginal ultrasound, or transabdominal ultrasound. Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)
Secondary Mean Percentage Change From Baseline in Uterine Volume at Month 3, Month 6, and Final Visit Uterine volume, as measured by transvaginal ultrasound or transabdominal ultrasound. Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)
Secondary Percentage of Participants With = 25% Reduction From Baseline in Total Fibroid Volume at Month 3, Month 6, and Final Visit Total fibroid volume (3 largest fibroids) was measured by transvaginal ultrasound, or transabdominal ultrasound. Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)
Secondary Percentage of Participants With = 25% Reduction From Baseline in Primary Fibroid Volume at Month 3, Month 6, and Final Visit Volume of the largest fibroid (primary fibroid) was measured by transvaginal ultrasound or transabdominal ultrasound. Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)
Secondary Percentage of Participants With = 25% Reduction From Baseline in Uterine Volume at Month 3, Month 6, and Final Visit Uterine volume was measured by transvaginal ultrasound or transabdominal ultrasound. Baseline, Month 3, Month 6, and Final Visit during treatment period (Month 6 or early termination)
Secondary Change From Baseline to Each Month in Non-Bleeding Uterine Fibroids Symptom (NBUFSQ) Questionnaire The NBUFSQ (8 items) is a brief patient-reported daily diary that assesses non-bleeding symptoms experienced by women with uterine fibroids. It includes 6 items, asking women to rate their symptoms (abdominal/pelvic pain, pressure, and cramping, back pain, bloating, and urinary problems) in the past 24 hours using an 11-point numeric response scale that ranges from 0 (i.e., no symptom) to 10 (i.e., worst possible symptom) and 2 items to address urinary frequency during the daytime and at night. Data presented in the sum of scores to the 6 symptom questions, ranging from 0 (no symptoms) to 60 (worst possible symptoms). Baseline is defined as the last 28 days prior to the first day of study drug. Final Month is defined as the last 28 days prior to and including the last dose date of study drug. Baseline, Days 1-28, Days 29-56, Days 57-84, Days 85-112, Days 113-140, Days 141-168, Final Month of treatment, Post-treatment (PT) Days 1-28, PT Days 29-56, PT Days 57-84, PT Days 85-112, PT Days 113-140, PT Days 141-168
Secondary Percentage of Participants Who Successfully Avoided Surgical or Invasive Procedures for Uterine Fibroids The percentage of participants who successfully avoided surgical or invasive procedures for Uterine Fibroids was assessed. Month 6
See also
  Status Clinical Trial Phase
Completed NCT01441635 - Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids Phase 2
Completed NCT00958334 - Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003 Phase 2
Withdrawn NCT04567589 - A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Healthcare Professionals in Canada
Recruiting NCT05078307 - Evaluation of a Hysteroscopic Method With Vaporization in the Hysteroscopic Treatment of Submucosal Uterine Fibroids N/A
Recruiting NCT02283502 - Clinical Test of the MRgHIFU System on Uterine Fibroids Phase 1
Completed NCT01739621 - Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200 Phase 2
Completed NCT01631903 - Extension of Study ZPV-200 Phase 2
Withdrawn NCT00768742 - Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study N/A
Completed NCT00152256 - A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids Phase 3
Not yet recruiting NCT03586947 - Association Between Vitamin D and the Risk of Uterine Fibroids N/A
Completed NCT02925494 - An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Phase 3
Not yet recruiting NCT06055114 - Study on Vaginal Microecology and Cervical Local Immune Function in Patients With Uterine Fibroids of Childbearing Age
Terminated NCT05026502 - A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules
Withdrawn NCT04567095 - A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Patients in Canada
Withdrawn NCT03699176 - Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Phase 3
Not yet recruiting NCT02884960 - Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization N/A
Completed NCT02472184 - Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy N/A
Completed NCT01452659 - Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids Phase 2
Terminated NCT01555073 - Preemptive Analgesia Following Uterine Artery Embolization Phase 4
Completed NCT01229826 - Magnetic Resonance Elastography (MRE) of Uterine Fibroids N/A